What Healthcare Boards Need to Know Before Approving AI Strategy

If I were on a healthcare board, I’d treat AI approval as a risk vote, not a tech vote. That’s the core point. With predictive AI use moving from 66% in 2023 to 71% in 2024, boards need proof that management has clear owners, vendor checks, privacy controls, patient-safety testing, and board reporting before any approval.

Here’s the short version: I would not approve an AI plan unless I could see that:

• Each AI use case has a named owner
• Board committees know who reviews what
• AI vendors have been checked beyond a normal security review
• PHI use, BAAs, and data limits are documented
• Clinical tools were tested on the health system’s own patient population
• There is a written rollback plan if a tool causes harm or fails
• The board will get regular metrics after approval

A few facts make this urgent:

• 66% of boards report limited AI fluency
• In 2023, 58% of the 77.3 million people affected by healthcare data breaches were hit through business associates
• One outside review found the Epic Sepsis Model missed nearly two-thirds of sepsis cases

So, my takeaway is simple: no approval without proof. I’d want to see governance documents, third-party risk management summaries, model testing records, privacy reviews, cyber controls, and incident procedures before any vote.

That’s the standard the rest of this article supports.

Health Care Corporate Governance: Critical New AI-Related Issues for Health Care Boards

sbb-itb-535baee

1. Governance and Accountability Structures Boards Must See First

An AI strategy without clear ownership is an unmanaged risk. Before a board signs off, it needs named leaders and written escalation authority, including the power to stop a deployment.

Name the Owners Across Executive, Clinical, Security, Compliance, and Privacy Functions

Boards should ask management to name specific people, plus backup owners, for AI oversight. At a minimum, that includes a single executive AI owner who is accountable for enterprise-wide governance and board reporting ^[5], a clinical safety lead - often the CMIO or CQO - who owns clinical validation and required human review ^[6], a compliance leader who handles regulatory review and audit records ^[2][3], and legal counsel who advises on contracts, liability, and consent language ^[3].

Boards should also check that security, privacy, risk, and other review teams have clear escalation paths inside the same governance structure.

Each role needs clear authority to approve use cases, track performance, and respond to incidents. If even one of those three jobs is unassigned, there’s a hole in the governance model.

Those owners should show up clearly in the policy, charter, and escalation path the board reviews next.

Review the Governance Documents That Make Oversight Real

Named owners, by themselves, don’t do much. Boards should ask for a core governance package before voting. That package should include:

• An AI governance policy
• A use case inventory with risk classifications
• Risk tiering criteria tied to patient safety and regulatory exposure
• A committee charter with clear decision rights
• An incident escalation protocol
• Documented required human review points for higher-risk use cases

A written validation gate should catch failures before deployment. The Epic Sepsis Model shows why that matters. An independent evaluation found that it missed nearly two-thirds of sepsis cases and generated many false alerts ^[6][8]. That’s exactly the kind of problem a written risk-tiering process and clinical validation rule should flag before a tool goes live.

Once those documents are in place, boards should pressure-test whether third-party AI risk has its own controls.

Set a Board Oversight Schedule Instead of a One-Time Approval

Approval isn’t the finish line. The American Hospital Association has noted that:

"most hospital and health system boards lack a clear framework for overseeing AI risks and opportunities" ^[7][9]

Boards should make AI a standing board agenda item. That means regular dashboard reporting on key risk metrics, a set threshold for incident escalation, and a formal annual AI risk review. HHS’s own AI Governance Board uses this kind of model at the federal level, keeping a department-wide use-case inventory and applying transparent, risk-based controls to streamline approvals ^[4]. Healthcare boards should expect the same level of discipline from management.

That oversight should carry through vendor review, model review, and incident review. The same cadence should apply to cybersecurity and third-party AI risk.

2. Cybersecurity and Third-Party AI Risk Require Separate Scrutiny

Once ownership is clear, boards need a separate check for AI cyber and vendor risk. Most healthcare AI plans rely on outside vendors, cloud platforms, and embedded models. In 2023, 58% of the 77.3 million individuals affected by healthcare data breaches were impacted through attacks on healthcare business associates, a 287% increase over 2022 ^[10]. AI doesn't shrink that exposure. It adds more places where things can go wrong.

Ask How Management Has Assessed AI-Specific Cyber Threats

AI systems open attack paths that standard security reviews often miss. Boards should ask management for documented reviews of AI-specific threats, grouped into three buckets: model integrity risks, access and integration risks, and supply-chain risks ^[11][15][17].

That means looking at issues such as data poisoning, adversarial examples, and model theft on the model side; prompt injection, insecure APIs, and unauthorized access on the access side; and third-party compromise or weak monitoring on the supply-chain side ^[11][15][17]. In healthcare, AI models can be compromised with 100–500 poisoned samples, and those compromises may stay hidden for months or longer if no one is watching for them in a targeted way ^[13].

Management should also map these threats to NIST's AI Risk Management Framework (AI RMF), which covers prompt injection, data leakage, insecure APIs, model theft, unauthorized access, and supply-chain compromise across the AI lifecycle ^[11][12][16]. Those risks should shape vendor due diligence from the start, not be treated as a separate issue off to the side.

Require Vendor Due Diligence That Goes Beyond Standard Security Reviews

A standard security questionnaire is not enough for AI vendors. Boards should ask management to show how each vendor was reviewed using AI-specific assessments, SBOM requests, contract terms that spell out cybersecurity duties, and continuous monitoring of vendor posture, including AI-enabled products ^{[14][18][19][20][21]}.

There's a basic problem here: many healthcare organizations still do not have a complete AI vendor inventory. They also lack a clear view of where AI is embedded and what data it touches ^[14][18]. If you don't know which tools use AI, or where patient data flows, it's hard to judge risk with any confidence.

Standardize AI Vendor Assessments and Risk Reporting

One-off vendor reviews leave blind spots. Management should give the board comparable risk summaries across all AI vendors, with the same core fields each time:

• control gaps
• remediation timelines
• residual risk ratings
• named owners

Without that shared format, boards can't tell if one vendor's risk profile is much worse than another's. Censinet RiskOps™ and Censinet AI can help structure AI vendor assessments, validate evidence, capture integration and fourth-party exposures, and produce board-ready risk summaries [Censinet]. Before go-live, the approval package should show open gaps, owners, remediation dates, and residual risk.

3. Compliance, Data Privacy, and Patient Safety Are Approval Gates

If regulatory, privacy, and patient-safety duties haven't been mapped, the strategy isn't ready for board approval. Governance and vendor controls matter. But when the compliance picture is still blurry, approving the plan is too soon.

Confirm the Regulatory Scope for Each AI Use Case

Boards shouldn't vote until management has mapped the legal, privacy, and clinical duties tied to each use case. That means a written determination showing which laws and FDA rules apply to every AI tool, including the HIPAA Privacy Rule for permitted uses and disclosures of PHI and the minimum necessary standard, the HIPAA Security Rule for encryption, access controls, and audit logs, and whether the tool counts as clinical decision support or software as a medical device under FDA oversight.^{[28][29][31][34]}

Not all AI tools carry the same level of risk. A tool that helps shape diagnosis or treatment faces a much higher bar than one that only offers informational support. Management should show a clear regulatory classification for each tool, including whether premarket submissions, human factors testing, or post-market surveillance plans are required.^[29][34] That classification tells the board what controls should be in place before any approval.

Verify Data Privacy Controls for PHI and Sensitive Operational Data

Boards should ask for PHI and sensitive-data controls that go past baseline HIPAA compliance. At a minimum, management should show:

• Data minimization policies that spell out which datasets may be used for training and inference
• Role-based access controls that separate clinical users from data scientists and vendors
• Strong encryption for AI data stores, model files, and related outputs
• Written retention limits and destruction procedures for training data^[22][25][26]

De-identification also needs its own review. HIPAA allows two methods: Safe Harbor, which removes 18 specific identifiers, and Expert Determination, where a qualified expert finds that re-identification risk is very small.^[30] Boards should see which method was used, how re-identification risk was tested, and why management believes the result can be trusted.

This matters because modern AI methods can sometimes reconnect de-identified records when datasets are merged.^[23][24][27] A policy statement alone isn't enough. The board should ask for proof of re-identification risk testing.

One control often slips through the cracks: a clear policy banning PHI uploads into public or general-purpose AI tools unless those tools are covered by a HIPAA-compliant business associate agreement with strict data-use terms.^[33] Those controls only mean something if the board can inspect the documents behind them.

Require Patient Safety Testing, Monitoring, and Rollback Procedures

For any clinical AI tool, boards should require pre-deployment validation using the organization's own patient population, not just a vendor's internal benchmark data. That review should include accuracy, sensitivity, and specificity results, along with performance breakdowns by demographic subgroup, such as race, sex, age, and comorbidities, so bias can be found before it affects patients.^[1][32][35]

After go-live, boards should require:

• Continuous drift detection
• Tracking of close calls and unsafe outputs
• Written clinician override procedures
• A rollback procedure that states who can remove the tool, when they can do it, and how fast^[1][32][35]

If that rollback procedure doesn't exist before approval, the board is taking on risk without a safety net. The supporting evidence should be on the table before any approval vote.

4. The Evidence Package and Metrics Boards Should Review Before Approval

Once governance, cyber, privacy, and safety controls are set, the board needs proof that those controls are written down and working. A board should not approve an AI strategy from a pitch deck alone. It should ask for evidence that risk has been identified, measured, and kept under control.

Ask for a Minimum Approval Package, Not a Pitch Deck

An approval packet is different from a pitch deck in one basic way: it shows proof of control, not just plans and promises. This is how boards can see whether management has moved from policy into day-to-day execution.

At a minimum, the board should ask for these eight document sets before any approval vote:

If even one of these items is missing or unfinished, the strategy is not ready for a formal approval vote.

Use a Board Questions-to-Evidence Table to Test Readiness

A questions-to-evidence table gives the board a simple way to pressure-test readiness during the meeting. Instead of asking broad questions and getting broad answers, directors can tie each question to a document, a named owner, and a clear threshold for approval.

This kind of table changes the tone of the discussion. It pushes management to show receipts, not just talk through intent.

Track the Metrics That Show Whether AI Risk Is Under Control

Approval should start monitoring, not end it. After approval, board oversight depends on regular measurement. Boards should get a short AI risk dashboard at least quarterly, plus ad hoc updates after any major incident or any major expansion of the AI portfolio. The NIST AI Risk Management Framework's Measure function says this plainly: organizations should show how they measured performance, what they found, and what changed as a result.^[36]

A board-level AI risk dashboard should include:

• The number of AI systems in production by risk tier, with quarter-over-quarter change
• Open high and critical findings, segmented by domain and age
• AI-related cyber incidents and remediation status
• Patient safety events or near misses tied to AI outputs
• Median remediation time for critical gaps
• The share of AI vendors with completed due diligence and current BAAs^[37][38]

For high-risk clinical systems, the dashboard should also include post-launch drift and bias indicators. That means prediction accuracy decay, fairness gaps across demographic groups, and time to detect anomalies.^[37][39]

A centralized risk platform can pull together AI policies, risks, tasks, and findings for board reporting.

Conclusion: Boards Should Approve AI Strategy Only When Controls Match the Risk

Approving an AI strategy is an enterprise risk decision, not an innovation vote. That means it sits squarely in the board’s risk process. Why? Because AI can affect patient safety, compliance, cyber exposure, and financial stability all at once.

The decision rule is pretty simple: approve only when controls match the risk. If governance is vague, vendor terms are weak, privacy protections are incomplete, or validation work isn’t finished, the right call is to defer. Even if the business case looks strong. Strategic ambition can’t run ahead of control readiness.

That standard points to four approval gates. The board should look for proof in four areas:

• Clear governance
• AI-specific cyber and vendor controls
• Use-case-level compliance and safety validation
• A documented evidence package with ongoing monitoring

The board’s test is direct: no approval without proof that governance, security, privacy, and safety controls fit the risk of the use case.

If those gates are in place, the board can move ahead responsibly. Approval is the start of oversight, not the finish line. When management can show a documented inventory, clear ownership, tested safeguards, and measurable monitoring, the board can approve with conditions and set a scheduled re-review. That’s how healthcare organizations move ahead on AI without letting speed outrun safety.

FAQs

What makes AI approval a board risk decision?

AI approval is a board-level risk decision because it can affect clinical safety, cybersecurity, and legal liability. If it goes wrong, the fallout can be serious: patient harm, regulatory violations, and financial exposure.

This is not the same as a standard IT project. AI brings its own set of risks, including automation bias, model drift, and third-party vendor issues. That’s why boards need to provide formal oversight, set clear risk limits, and make sure ownership and audit trails are clearly defined.

Which AI use cases need the most board scrutiny?

Healthcare boards should focus first on AI use cases that carry the most risk for clinical harm, privacy exposure, and regulatory liability.

That means paying close attention to diagnostic AI, ambient documentation tools, and triage or routing models. These systems handle PHI and can shape diagnosis, treatment decisions, or whether a patient’s care gets escalated.

Because the stakes are high, boards should require:

• Local validation before use
• Bias testing
• Documented clinician review policies

This isn’t just a governance box to check. If an AI tool can influence care, boards need clear proof that it works safely in their own setting.

What proof should management show before approval?

Before approval, management should show documented proof that the AI strategy or tool is safe, compliant, and ready for use in day-to-day operations.

That proof should cover the tool’s intended use, where the data came from, and how it was validated on the organization’s own patient population. It should also spell out bias testing, clinician override options, controls for hallucinations, and plans for monitoring and rollback if something goes wrong.

There should also be clear ownership. In plain English, someone needs to be on the hook. That means named owners, defined escalation paths, a risk register, and audit trails.

If the tool comes from a third party, the review needs to go further. Management should provide:

• a security review
• a signed BAA
• a subprocessor list
• model governance evidence

Put simply, approval shouldn’t rest on promises alone. It should rest on records, named accountability, and a paper trail that can stand up to scrutiny.

Related Blog Posts

• Clinical Intelligence: Using AI to Improve Patient Care While Managing Risk
• The Future of Healthcare AI Will Be Governed or It Will Be Dangerous
• Why Recent Cyber Events Are Reshaping the AI Risk Conversation in Healthcare
• Why Board-Level Oversight Is Now Central to Healthcare AI Governance